TS-172 20~60 mg/day

DRUG3 trials

Sponsors

Taisho Pharmaceutical Co., Ltd.

Conditions

Hyperphosphatemia Patients on Hemodialysis

Phase 3

A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

CompletedNCT06745531

Taisho Pharmaceutical Co., Ltd.Hyperphosphatemia Patients on Hemodialysis

Start: 2025-01-06End: 2025-10-20Updated: 2025-11-17

A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders

RecruitingNCT07285291

Taisho Pharmaceutical Co., Ltd.Hyperphosphatemia Patients on Hemodialysis

Start: 2026-01-09End: 2026-12-29Target: 100Updated: 2026-04-17

A Clinical Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

RecruitingNCT07548840

Taisho Pharmaceutical Co., Ltd.Hyperphosphatemia Patients on Hemodialysis

Start: 2026-05-08End: 2026-11-30Target: 30Updated: 2026-05-15